8-K: Lyell Immunopharma Implements 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing

Lyell Immunopharma, Inc. has filed a Certificate of Amendment to effect a 1-for-20 reverse stock split of its common stock, effective May 30, 2025, with trading on a split-adjusted basis commencing June 2, 2025.

Summary

• Lyell Immunopharma, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation on May 27, 2025, to effect a 1-for-20 reverse stock split of its outstanding common stock.
• The reverse stock split was authorized by the company's stockholders at the 2025 Annual Meeting held on May 15, 2025.
• The split will become effective at 5:00 p.m. Eastern Time on May 30, 2025, converting every 20 shares into one share without changing the par value.
• Trading of the company's common stock on The Nasdaq Global Select Market will begin on a split-adjusted basis when the market opens on June 2, 2025.
• No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment in lieu thereof.
• Proportionate adjustments will be made to the per share exercise price and number of shares for all outstanding stock options and restricted stock units, as well as shares reserved under equity incentive plans.
• As of May 27, 2025, there were 296,161,570 shares of common stock outstanding; immediately following the split, this number will be approximately 14,808,078 shares (subject to fractional share adjustments).

Sentiment

Score: 4

Explanation: While necessary for Nasdaq compliance, a reverse stock split often indicates a significant decline in share price and does not fundamentally improve the company's business operations or financial health. It's a reactive measure rather than a proactive positive development.

Positives

• The reverse stock split is a necessary action to increase the per-share price, which is typically done to meet minimum bid price requirements of stock exchanges like Nasdaq, thereby preventing potential delisting.
• A higher share price may make the stock more attractive to institutional investors and funds that have policies against investing in 'penny stocks'.

Negatives

• A reverse stock split often signals a significant decline in the company's stock price, indicating underlying market concerns or operational challenges.
• The split does not fundamentally change the company's business operations, financial health, or intrinsic value.
• There is no guarantee that the stock price will remain elevated post-split; it may continue to decline if fundamental issues persist.

Risks

• The primary risk is that the stock price may continue to decline after the reverse split, potentially falling below Nasdaq's minimum bid price again, leading to further compliance issues or eventual delisting.
• The cash payment for fractional shares means some stockholders may lose their equity position if their share count falls below the split ratio threshold.
• A reverse split can sometimes be perceived negatively by the market, potentially deterring retail investors.

Future Outlook

The reverse stock split is intended to increase the per-share trading price of Lyell Immunopharma's common stock, which is typically a measure taken to ensure compliance with Nasdaq's minimum bid price requirements and potentially enhance the stock's appeal to a broader range of investors.

Management Comments

• The Charter Amendment was authorized by the stockholders of the Company at the Company's 2025 Annual Meeting of Stockholders held on May 15, 2025.
• Lyell Immunopharma, Inc. caused this Certificate of Amendment to be executed by its President and Chief Executive Officer as of May 27, 2025 (signed by Charles Newton, CFO).

Industry Context

Reverse stock splits are a common corporate action, particularly for biotechnology companies, when their stock price falls below the minimum bid price required by major exchanges like Nasdaq (typically $1.00). This action is primarily aimed at maintaining listing compliance and can sometimes improve the stock's perception among institutional investors who may avoid lower-priced shares. However, it does not address the underlying business fundamentals that led to the low share price.

Comparison to Industry Standards

• Many small-cap biotechnology and pharmaceutical companies, especially those in clinical development stages without significant revenue, face challenges in maintaining their stock price above exchange minimums.
• Reverse stock splits, such as the 1-for-20 ratio implemented by Lyell Immunopharma, are a standard mechanism used by companies across various industries, including biotech, to regain compliance with exchange listing rules.
• Comparable companies that have undertaken similar reverse splits often do so after prolonged periods of stock price decline, aiming to avoid delisting and potentially attract new investment, though the long-term success of such actions varies widely based on the company's underlying business performance and pipeline progress.

Corporate Governance

Stakeholder Impact

• Shareholders will own fewer shares but their percentage ownership of the company's common stock will remain proportionately the same (except for those holding only fractional shares).
• Stockholders who would otherwise receive a fractional share will receive a cash payment in lieu thereof, potentially leading to a small loss of equity for some.
• Holders of stock options and restricted stock units will see their awards adjusted proportionately, meaning fewer shares but a higher exercise price for options, maintaining the intrinsic value of their awards.

Next Steps

• The company's common stock will begin trading on The Nasdaq Global Select Market on a split-adjusted basis when the market opens on June 2, 2025.

Key Dates

Recommendation

Keywords

Lyell Immunopharma, reverse stock split, common stock, Nasdaq, share consolidation, corporate action, equity, stock market, biotechnology, immunotherapy